Expressing concern over the rise in active COVID-19 cases in a few states, including Maharashtra, the Centre on Thursday advised people to be "careful and watchful" and not lower guard as the pandemic is not yet over.
At a press conference, NITI Aayog member (Health) V K Paul termed the coronavirus situation, especially in Maharashtra, "worrisome".
"We are very worried about the rise in cases in Maharashtra.
Don't take this virus for granted.
It can come up unexpectedly.
If we have to remain free of this virus, COVID-appropriate behavior, containment strategy as well as vaccination has to be brought in," Paul said.
Maharashtra reported 67,123 fresh COVID cases, 56,783 discharges, and 419 deaths on April 17. While Maharashtra's capital reported 8,834 new COVID-19 cases, 6,617 discharges and 52 deaths in last 24 hours. On the other side, Karnataka today registered 17,489 new positive cases, 5,565 discharges and 80 deaths. Kerala also reported 13,835 new cases, 3654 recoveries and 27 deaths today. Meanwhile, Madhya Pradesh reported 11,269 new coronavirus cases, 6,497 recoveries, and 66 deaths in last 24 hours.
While lockdown-like restrictions are in place in Maharashtra, Lokmanya Tilak Terminus remains crowded. Several migrant workers await their respective trains outside the station. Restrictions were imposed in view of rising COVID cases in Maharashtra.
The Central Government has given permission to Haffkine Institute to produce Bharat Biotech's Covaxin. CM Uddhav Thackeray thanked PM Modi through a tweet by CM office, Maharashtra on April 15, "The Dept of Science and Technology, Government of India, has granted approval to Haffkine Institute to produce Bharat Biotech's Covaxin vaccine on a transfer of technology basis. CM Uddhav Balasaheb Thackeray has thanked the Hon'ble PM Shri@narendramodi for approving this request."
During press conference held in Delhi, Niti Aayog's Dr VK Paul spoke on Remdesivir, which is an anti-viral drug for COVID-19. "There is no question of use of Remdesivir in home setting. This is required for those individuals who require hospitalisation and are on oxygen. It should only be use in hospital and not to be procured from chemist shops. We appeal that there should be rational use of Remdesivir. The drug is available in sufficient numbers. We appeal to the physicians' community for rational, judicious, and correct use of the drug," said Dr VK Paul.
The Centre on Tuesday said doctors should ensure "rational and judicious" use of anti-viral drug Remdesivir, underlining it is to be given only to serious COVID-19 patients in hospitals and is not to be used in home settings. NITI Aayog member (Health) Dr V K Paul said, "Remdesivir is to be used only in those who require hospitalisation and are on oxygen support. That is the precondition. There is no question of its use in the home setting and for mild cases, and it is not to be procured from chemist shops." "We appeal to physicians to ensure rational, correct and judicious use of Remdesivir in hospitalised patients," he said. Watch the full video for more details.
Credit: HT Digital Content Duration: 06:23Published
While addressing a joint press conference in the national capital on March 24, the member of (Health) in NITI Aayog, Dr Vinod K Paul said there is no shortage of COVID vaccines in the country. Dr Paul said, "We have adequate supplies of vaccine for the COVID-19 vaccination program that has been brought forth." "There is no inadequacy of vaccine supply," he added.